Henri m H Spronk

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/4243112/henri-m-h-spronk-publications-by-year.pdf
Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

116 papers	4,218 citations	34 h-index	63 g-index
133 ext. papers	5,011 ext. citations	7.1 avg, IF	5.43 L-index

#	Paper	IF	Citations
116	Effect of combining aspirin and rivaroxaban on atherosclerosis in mice.. *Atherosclerosis*, **2022**, 345, 7-14	3.1	0
115	Protein C or Protein S deficiency associates with paradoxically impaired platelet-dependent thrombus and fibrin formation under flow.. *Research and Practice in Thrombosis and Haemostasis*, **2022**, 6, e12678	5.1	
114	Thrombin generation by calibrated automated thrombography in goat plasma: Optimization of an assay. *Research and Practice in Thrombosis and Haemostasis*, **2021**, 5, e12620	5.1	
113	Pleiotropic actions of factor Xa inhibition in cardiovascular prevention: mechanistic insights and implications for anti-thrombotic treatment. *Cardiovascular Research*, **2021**, 117, 2030-2044	9.9	4
112	Thrombin-Fibrin(ogen) Interactions, Host Defense and Risk of Thrombosis. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	4
111	Off-target effects of oral anticoagulants - vascular effects of vitamin K antagonist and non-vitamin K antagonist oral anticoagulant dabigatran etexilate. *Journal of Thrombosis and Haemostasis*, **2021**, 19, 1348-1363	15.4	5
110	Serial EXTEM, FIBTEM, and tPA Rotational Thromboelastometry Observations in the Maastricht Intensive Care COVID Cohort-Persistence of Hypercoagulability and Hypofibrinolysis Despite Anticoagulation. *Frontiers in Cardiovascular Medicine*, **2021**, 8, 654174	5.4	9
109	No antiarrhythmic effect of direct oral anticoagulants versus vitamin K antagonists in paroxysmal atrial fibrillation patients undergoing catheter ablation. *International Journal of Cardiology*, **2021**, 331, 106-108	3.2	
108	Suggestions for global coagulation assays for the assessment of COVID-19 associated hypercoagulability. *Thrombosis Research*, **2021**, 201, 84-89	8.2	8
107	Evaluation of the analytical performance of the PC100 platelet counter. *Thrombosis Journal*, **2021**, 19, 29	5.6	
106	Serial markers of coagulation and inflammation and the occurrence of clinical pulmonary thromboembolism in mechanically ventilated patients with SARS-CoV-2 infection; the prospective Maastricht intensive care COVID cohort. *Thrombosis Journal*, **2021**, 19, 35	5.6	5
105	Potent Cyclic Peptide Inhibitors of FXIIa Discovered by mRNA Display with Genetic Code Reprogramming. *Journal of Medicinal Chemistry*, **2021**, 64, 7853-7876	8.3	3
104	The impact of platelet indices on clinical outcome in heart failure: results from the MyoVasc study. *ESC Heart Failure*, **2021**, 8, 2991-3001	3.7	1
103	Relation between Tissue Factor Pathway Inhibitor Activity and Cardiovascular Risk Factors and Diseases in a Large Population Sample. *Thrombosis and Haemostasis*, **2021**, 121, 174-181	7	2
102	The Intrinsic Pathway does not Contribute to Activation of Coagulation in Mice Bearing Human Pancreatic Tumors Expressing Tissue Factor. *Thrombosis and Haemostasis*, **2021**, 121, 967-970	7	1
101	Calibrated automated thrombogram II: removing barriers for thrombin generation measurements. *Thrombosis Journal*, **2021**, 19, 60	5.6	1
100	Activated factor XI-antithrombin complex presenting as an independent predictor of 30-days mortality in out-of-hospital cardiac arrest patients. *Thrombosis Research*, **2021**, 204, 1-8	8.2	1

99	ChAdOx1 vaccination, blood coagulation, and inflammation: No effect on coagulation but increased interleukin-6.. *Research and Practice in Thrombosis and Haemostasis*, **2021**, 5, e12630	5.1	1
98	Role of Factor XIa and Plasma Kallikrein in Arterial and Venous Thrombosis. *Thrombosis and Haemostasis*, **2020**, 120, 883-993	7	10
97	Temporal patterns and short-term progression of paroxysmal atrial fibrillation: data from RACE V. *Europace*, **2020**, 22, 1162-1172	3.9	14
96	Additive effect of erythropoietin use on exercise-induced endothelial activation and hypercoagulability in athletes. *European Journal of Applied Physiology*, **2020**, 120, 1893-1904	3.4	
95	Plasma Biomarkers to Predict Cardiovascular Outcome in Patients With Peripheral Artery Disease: A Systematic Review and Meta-Analysis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2020**, 40, 2018-2032	9.4	17
94	Atrial fibrillation progression risk factors and associated cardiovascular outcome in well-phenotyped patients: data from the AF-RISK study. *Europace*, **2020**, 22, 352-360	3.9	23
93	Plasma Kallikrein Contributes to Coagulation in the Absence of Factor XI by Activating Factor IX. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2020**, 40, 103-111	9.4	15
92	Platelet-primed interactions of coagulation and anticoagulation pathways in flow-dependent thrombus formation. *Scientific Reports*, **2020**, 10, 11910	4.9	11
91	Thrombin generation in cardiovascular disease and mortality - results from the Gutenberg Health Study. *Haematologica*, **2020**, 105, 2327-2334	6.6	15
90	Neutrophils and Contact Activation of Coagulation as Potential Drivers of COVID-19. *Circulation*, **2020**, 142, 1787-1790	16.7	46
89	Comprehensive platelet phenotyping supports the role of platelets in the pathogenesis of acute venous thromboembolism - results from clinical observation studies. *EBioMedicine*, **2020**, 60, 102978	8.8	8
88	Thrombo-Inflammation in Cardiovascular Disease: An Expert Consensus Document from the Third Maastricht Consensus Conference on Thrombosis. *Thrombosis and Haemostasis*, **2020**, 120, 538-564	7	39
87	Differential roles of factors IX and XI in murine placenta and hemostasis under conditions of low tissue factor. *Blood Advances*, **2020**, 4, 207-216	7.8	4
86	Volume replacement strategies do not impair the binding of dabigatran to idarucizumab: Porcine model of hemodilution. *PLoS ONE*, **2019**, 14, e0209350	3.7	
85	Use of "C9/11 Mismatch" Control siRNA Reveals Sequence-Related Off-Target Effect on Coagulation of an siRNA Targeting Mouse Coagulation Factor XII. *Nucleic Acid Therapeutics*, **2019**, 29, 218-223	4.8	2
84	Searching for a Common Thrombo-Inflammatory Basis in Patients With Deep Vein Thrombosis or Peripheral Artery Disease. *Frontiers in Cardiovascular Medicine*, **2019**, 6, 33	5.4	4
83	Mouse venous thrombosis upon silencing of anticoagulants depends on tissue factor and platelets, not FXII or neutrophils. *Blood*, **2019**, 133, 2090-2099	2.2	16
82	Targeting Coagulation Factor Xa Promotes Regression of Advanced Atherosclerosis in Apolipoprotein-E Deficient Mice. *Scientific Reports*, **2019**, 9, 3909	4.9	24

81	Proteomic analysis reveals procoagulant properties of cigarette smoke-induced extracellular vesicles. *Journal of Extracellular Vesicles*, **2019**, 8, 1585163	16.4	21
80	Plasma Kallikrein Contributes to Ellagic Acid-Induced Coagulation in the Absence of FXI By Activating Factor IX. *Blood*, **2019**, 134, 1106-1106	2.2	
79	Novel Thermostable Inhibitor of Contact Activation Tica Effectively Blocks Contact Activation in Low Tissue Factor Thrombin Generation. *Blood*, **2019**, 134, 1146-1146	2.2	0
78	Relation between platelet coagulant and vascular function, sex-specific analysis in adult survivors of childhood cancer compared to a population-based sample. *Scientific Reports*, **2019**, 9, 20090	4.9	
77	Roles of Coagulation Proteases and PARs (Protease-Activated Receptors) in Mouse Models of Inflammatory Diseases. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2019**, 39, 13-24	9.4	44
76	Protease-activated receptors are potential regulators in the development of arterial endofibrosis in high-performance athletes. *Journal of Vascular Surgery*, **2019**, 69, 1243-1250	3.5	3
75	Cardiovascular risk factors are important determinants of platelet-dependent thrombin generation in adult survivors of childhood cancer. *Clinical Research in Cardiology*, **2019**, 108, 438-447	6.1	5
74	Clinical Determinants of Thrombin Generation Measured in Presence and Absence of Platelets-Results from the Gutenberg Health Study. *Thrombosis and Haemostasis*, **2018**, 118, 873-882	7	9
73	Dual Anticoagulant and Antiplatelet Therapy for Coronary Artery Disease and Peripheral Artery Disease Patients. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2018**, 38, 726-732	9.4	11
72	Detecting clinically relevant rivaroxaban or dabigatran levels by routine coagulation tests or thromboelastography in a cohort of patients with atrial fibrillation. *Thrombosis Journal*, **2018**, 16, 3	5.6	29
71	Plasminogen activator inhibitor-1 and tissue plasminogen activator and incident AF: Data from the PREVEND study. *International Journal of Cardiology*, **2018**, 272, 208-210	3.2	5
70	Lipid-Mediated Relation between Tissue Factor Pathway Inhibitor Activity and Cardiovascular Risk Factors and Diseases in a Large Population Sample. *Blood*, **2018**, 132, 1169-1169	2.2	
69	Interrogation of the Coagulation Cascade Acute Coronary Syndrome Using Novel Elisa-Based Assays for Single Protease Quantification. *Blood*, **2018**, 132, 5013-5013	2.2	
68	Characterization of hemostasis in mice lacking the novel thrombosis susceptibility gene Slc44a2. *Thrombosis Research*, **2018**, 171, 155-159	8.2	13
67	Intake of Vitamin K Antagonists and Worsening of Cardiac and Vascular Disease: Results From the Population-Based Gutenberg Health Study. *Journal of the American Heart Association*, **2018**, 7, e008650	6	8
66	Inhibitory mechanisms of very low-dose rivaroxaban in non-ST-elevation myocardial infarction. *Blood Advances*, **2018**, 2, 715-730	7.8	24
65	Integrating platelet and coagulation activation in fibrin clot formation. *Research and Practice in Thrombosis and Haemostasis*, **2018**, 2, 450-460	5.1	68
64	Pleiotropic effects of the hemostatic system. *Journal of Thrombosis and Haemostasis*, **2018**, 16, 1464	15.4	10

63	No Association between Thrombin Generation and Intra-Plaque Haemorrhage in Symptomatic Carotid Atherosclerotic Plaques: The Plaque at RISK (PARISK) Study. *Thrombosis and Haemostasis*, **2018**, 118, 1461-1469	7	7
62	Hypercoagulability causes atrial fibrosis and promotes atrial fibrillation. *European Heart Journal*, **2017**, 38, 38-50	9.5	89
61	Mean Platelet Volume and Arterial Stiffness - Clinical Relationship and Common Genetic Variability. *Scientific Reports*, **2017**, 7, 40229	4.9	12
60	Prethrombotic State in Young Very Low-Risk Patients With Atrial Fibrillation. *Journal of the American College of Cardiology*, **2017**, 69, 1990-1992	15.1	13
59	Dose requirements for idarucizumab reversal of dabigatran in a lethal porcine trauma model with continuous bleeding. *Thrombosis and Haemostasis*, **2017**, 117, 1370-1378	7	4
58	Increased Clot Formation in the Absence of Increased Thrombin Generation in Patients with Peripheral Arterial Disease: A Case-Control Study. *Frontiers in Cardiovascular Medicine*, **2017**, 4, 23	5.4	6
57	Effects of Fibrinogen Concentrate on Thrombin Generation, Thromboelastometry Parameters, and Laboratory Coagulation Testing in a 24-Hour Porcine Trauma Model. *Clinical and Applied Thrombosis/Hemostasis*, **2016**, 22, 749-759	3.3	10
56	Sex-specific differences in genetic and nongenetic determinants of mean platelet volume: results from the Gutenberg Health Study. *Blood*, **2016**, 127, 251-9	2.2	44
55	Validation of a modified thromboelastometry approach to detect changes in fibrinolytic activity. *Thrombosis Journal*, **2016**, 14, 1	5.6	40
54	Toll-like receptor 9 gene expression in the post-thrombotic syndrome, residual thrombosis and recurrent deep venous thrombosis: A case-control study. *Thrombosis Research*, **2016**, 140, 106-109	8.2	2
53	Factor XIa and Thrombin Generation Are Elevated in Patients with Acute Coronary Syndrome and Predict Recurrent Cardiovascular Events. *PLoS ONE*, **2016**, 11, e0158355	3.7	23
52	Therapy with activated prothrombin complex concentrate is effective in reducing dabigatran-associated blood loss in a porcine polytrauma model. *Thrombosis and Haemostasis*, **2016**, 115, 271-84	7	41
51	Hemostatic Therapy Using Tranexamic Acid and Coagulation Factor Concentrates in a Model of Traumatic Liver Injury. *Anesthesia and Analgesia*, **2016**, 123, 38-48	3.9	10
50	Role of platelets, neutrophils, and factor XII in spontaneous venous thrombosis in mice. *Blood*, **2016**, 127, 2630-7	2.2	24
49	Coagulation and non-coagulation effects of thrombin. *Journal of Thrombosis and Haemostasis*, **2016**, 14, 1908-1916	15.4	73
48	Distribution, genetic and cardiovascular determinants of FVIII:c - Data from the population-based Gutenberg Health Study. *International Journal of Cardiology*, **2015**, 187, 166-74	3.2	8
47	Short- and Long-term exercise induced alterations in haemostasis: a review of the literature. *Blood Reviews*, **2015**, 29, 171-8	11.1	53
46	Idarucizumab, a Specific Dabigatran Reversal Agent, Reduces Blood Loss in a Porcine Model of Trauma With Dabigatran Anticoagulation. *Journal of the American College of Cardiology*, **2015**, 66, 1518-9	15.1	49

45	Theme 2: Epidemiology, Biomarkers, and Imaging of Venous Thromboembolism (and postthrombotic syndrome). *Thrombosis Research*, **2015**, 136 Suppl 1, S8-S12	8.2	9
44	Prothrombin Complex Concentrate Is Effective in Treating the Anticoagulant Effects of Dabigatran in a Porcine Polytrauma Model. *Anesthesiology*, **2015**, 123, 1350-61	4.3	42
43	Recombinant Factor VIIa Reduces Bleeding after Blunt Liver Injury in a Pig Model of Dilutional Coagulopathy under Severe Hypothermia. *PLoS ONE*, **2015**, 10, e0113979	3.7	3
42	Associations Between Thrombin Generation and the Risk of Cardiovascular Disease in Elderly Patients: Results From the PROSPER Study. *Journals of Gerontology - Series A Biological Sciences and Medical Sciences*, **2015**, 70, 982-8	6.4	19
41	Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model. *Critical Care*, **2014**, 18, R27	10.8	80
40	Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants. *Cardiovascular Research*, **2014**, 101, 344-51	9.9	78
39	Thrombin generation and atherosclerosis. *Journal of Thrombosis and Thrombolysis*, **2014**, 37, 45-55	5.1	67
38	Measurement of dabigatran in standardly used clinical assays, whole blood viscoelastic coagulation, and thrombin generation assays. *Clinics in Laboratory Medicine*, **2014**, 34, 479-501	2.1	26
37	Differential cellular effects of old and new oral anticoagulants: consequences to the genesis and progression of atherosclerosis. *Thrombosis and Haemostasis*, **2014**, 112, 909-17	7	25
36	Long-term strenuous exercise induces a hypercoagulable state through contact activation. *Thrombosis and Haemostasis*, **2014**, 111, 1197-9	7	10
35	Differential roles of tissue factor and phosphatidylserine in activation of coagulation. *Thrombosis Research*, **2014**, 133 Suppl 1, S54-6	8.2	32
34	Prothrombin Complex Concentrate in Combination with Fibrinogen Plus Tranexamic Acid Is More Effective Than Mono-Therapy with Prothrombin Complex Concentrate in a Dabigatran Anticoagulation Experimental Polytrauma Model. *Blood*, **2014**, 124, 346-346	2.2	
33	Hypercoagulability Promotes Atrial Fibrosis and Fibrillation. *Blood*, **2014**, 124, 4246-4246	2.2	
32	New insights into modulation of thrombin formation. *Current Atherosclerosis Reports*, **2013**, 15, 363	6	15
31	Thrombin generation in the Glasgow Myocardial Infarction Study. *PLoS ONE*, **2013**, 8, e66977	3.7	23
30	Ex Vivo Prothrombin Complex Concentrates and a Specific Antidote Are Effective In Reversing Dabigatran-Induced Coagulopathy In Pigs. *Blood*, **2013**, 122, 2387-2387	2.2	2
29	Genetic and pharmacological modifications of thrombin formation in apolipoprotein e-deficient mice determine atherosclerosis severity and atherothrombosis onset in a neutrophil-dependent manner. *PLoS ONE*, **2013**, 8, e55784	3.7	87
28	Thrombin generation capacity of prothrombin complex concentrate in an in vitro dilutional model. *PLoS ONE*, **2013**, 8, e64100	3.7	32

27	Impaired glucose metabolism and type 2 diabetes are associated with hypercoagulability: potential role of central adiposity and low-grade inflammation--the Hoorn Study. *Thrombosis Research*, **2012**, 129, 557-62	8.2	30
26	Accelerated in vivo thrombin formation independently predicts the presence and severity of CT angiographic coronary atherosclerosis. *JACC: Cardiovascular Imaging*, **2012**, 5, 1201-10	8.4	49
25	Thrombin Inhibition Prevents Against Severe Atherosclerosis Progression in Prothrombotic Mice. *Blood*, **2012**, 120, 103-103	2.2	
24	The hemostatic system as a modulator of atherosclerosis. *New England Journal of Medicine*, **2011**, 364, 1746-60	59.2	385
23	Prothrombin complex concentrate reduces blood loss and enhances thrombin generation in a pig model with blunt liver injury under severe hypothermia. *Thrombosis and Haemostasis*, **2011**, 106, 724-33	7	29
22	Increasing concentrations of prothrombin complex concentrate induce disseminated intravascular coagulation in a pig model of coagulopathy with blunt liver injury. *Blood*, **2011**, 118, 1943-51	2.2	97
21	Particles, Coagulation, and Thrombosis **2011**, 403-420		
20	Body composition as determinant of thrombin generation in plasma: the Hoorn study. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2010**, 30, 2639-47	9.4	38
19	Early atherosclerosis exhibits an enhanced procoagulant state. *Circulation*, **2010**, 122, 821-30	16.7	151
18	Effects of ambient air pollution on hemostasis and inflammation. *Environmental Health Perspectives* , **2009**, 117, 995-1001	8.4	77
17	Activated protein C protects against myocardial ischemia/ reperfusion injury via inhibition of apoptosis and inflammation. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2009**, 29, 1087-92	9.4	65
16	Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia. *Haematologica*, **2009**, 94, 911-8	6.6	101
15	Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. *Cell*, **2009**, 139, 1143-56	36.2	605
14	Is thrombin a key player in the ‘coagulation-atherogenesis’ maze?. *Cardiovascular Research*, **2009**, 82, 392-403	9.9	148
13	Dual role of collagen in factor XII-dependent thrombus formation. *Blood*, **2009**, 114, 881-90	2.2	156
12	Monitoring thrombin generation: is addition of corn trypsin inhibitor needed?. *Thrombosis and Haemostasis*, **2009**, 101, 1156-62	7	20
11	Thrombin generation in patients after acute deep-vein thrombosis. *Thrombosis and Haemostasis*, **2008**, 100, 240-245	7	51
10	Assessment of thrombin generation II: Validation of the Calibrated Automated Thrombogram in platelet-poor plasma in a clinical laboratory. *Thrombosis and Haemostasis*, **2008**, 100, 362-364	7	69

9	Thrombomodulin-modified thrombin generation after in vivo recombinant factor VIII treatment in severe hemophilia A. *Haematologica*, **2008**, 93, 1351-7	6.6	15
8	Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. *Blood*, **2008**, 112, 4061-8	2.2	119
7	Thrombin generation in patients after acute deep-vein thrombosis. *Thrombosis and Haemostasis*, **2008**, 100, 240-5	7	27
6	Assessment of thrombin generation II: Validation of the Calibrated Automated Thrombogram in platelet-poor plasma in a clinical laboratory. *Thrombosis and Haemostasis*, **2008**, 100, 362-4	7	30
5	Analysis of blood coagulation in mice: pre-analytical conditions and evaluation of a home-made assay for thrombin-antithrombin complexes. *Thrombosis Journal*, **2005**, 3, 12	5.6	27
4	The prothrombotic paradox of hypertension: role of the renin-angiotensin and kallikrein-kinin systems. *Hypertension*, **2005**, 46, 1236-42	8.5	64
3	Blood coagulation and the risk of atherothrombosis: a complex relationship. *Thrombosis Journal*, **2004**, 2, 12	5.6	68
2	The blood coagulation system as a molecular machine. *BioEssays*, **2003**, 25, 1220-8	4.1	114
1	Novel mutation in the □-glutamyl carboxylase gene resulting in congenital combined deficiency of all vitamin K□dependent blood coagulation factors. *Blood*, **2000**, 96, 3650-3652	2.2	65